

Let's use health data better



- ✓ Strengthen your voice as patients through evidence
- ✓ Have easier and better conversations with doctors
- ✓ Compare with other patients

Using data to incorporate patient experience into healthcare decisions

Find out more at <https://health-outcomes-observatory.eu/>

or
Scan
here:



H2O has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF. www.ihl.europa.eu

DISCLAIMER: this infographic reflects only the author's view. Neither IMI, nor EFPIA, nor the European Commission, nor the JU are liable for any use that may be made of the information it contains.

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It works to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI was the world's biggest public-private partnership (PPP) in the life sciences until its successor, the Innovative Health Initiative (IHI), was established in 2021. www.ihl.europa.eu

Let's use health data better



H₂O

HEALTH OUTCOMES
OBSERVATORY



- ✓ Strengthen your voice as patients through evidence
- ✓ Have easier and better conversations with doctors
- ✓ Compare with other patients

Using data to incorporate patient experience into healthcare decisions

Find out more at
<https://health-outcomes-observatory.eu/>

or
Scan here:



H2O has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF. www.ihl.europa.eu

DISCLAIMER: this infographic reflects only the author's view. Neither IMI, nor EFPIA, nor the European Commission, nor the JU are liable for any use that may be made of the information it contains.

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It works to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI was the world's biggest public-private partnership (PPP) in the life sciences until its successor, the Innovative Health Initiative (IHI), was established in 2021. www.ihl.europa.eu

Healthcare decisions in the hands of patients



H₂O

HEALTH OUTCOMES
OBSERVATORY



- ✓ Enable multi-stakeholder use of patient-reported outcomes
- ✓ Assess quality of care across countries and diseases
- ✓ Foster a robust patient community

With and for patients



Find out more at
<https://health-outcomes-observatory.eu/>

or
**Scan
here:**



H2O has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF. www.ihl.europa.eu

DISCLAIMER: this infographic reflects only the author's view. Neither IMI, nor EFPIA, nor the European Commission, nor the JU are liable for any use that may be made of the information it contains.

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It works to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI was the world's biggest public-private partnership (PPP) in the life sciences until its successor, the Innovative Health Initiative (IHI), was established in 2021. www.ihl.europa.eu